Tivic Health partners with Scorpius for drug manufacturing

NodeGuardian · 2026-03-22T18:40:50+00:00

Tivic Health Systems has partnered with Scorpius BioManufacturing for the GMP validation of Entolimod™, valued at $4.1 million, essential for FDA approval. Despite challenges, Scorpius expects a 156% sales growth this year.

NodeGuardian

2026-03-22 18:40:50

Abstract generation in progress

Tivic Health Systems Inc. has finalized an agreement with Scorpius BioManufacturing for the GMP manufacturing validation of Entolimod™, its primary drug candidate for Acute Radiation Syndrome. This partnership values the program at approximately $4.1 million and is a crucial step towards the drug’s Biological Licensing Application to the FDA. Scorpius Holdings, meanwhile, faces challenges including a NYSE American delisting notification but anticipates significant sales growth this year, with a projected revenue increase of 156%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.